Ipcure
Develops selective caspase-2 inhibitors and research tools for life sciences researchers and drug development teams
Highlights
- Young companyFounded 2023
- New on EvolcAdded 2026-11-09
About Ipcure
IPCURE develops selective caspase-2 inhibitors for potential treatment of dementia and inflammatory diseases. Its Casp2i inhibitor and fluorogenic probe support research into caspase-2 function; Casp2i is sold for research use only.
The company is based in Paris, France, and was founded in 2023. It completed seed financing and received a Bourse French Tech Émergence grant.
Product: Selective caspase-2 inhibitors and a fluorogenic probe for research use, alongside drug development programmes targeting dementia and inflammatory diseases.
Jobs at Ipcure
Leadership
- Etienne D. Jacotot · Co-founder & CEOSource: company website
More biotech & pharma companies
Ipsomedic
Develops pharmaceutical active-ingredient manufacturing processes for domestic production in FranceNew on EvolcIris Pharma
Ophthalmology-focused preclinical and clinical research services for pharmaceutical and medical-device developersNew on EvolcJANVIER LABS
Supplies and manages experimental rodent models and related services for biomedical researchersNew on EvolcSalary transparentKcas Bio
Bioanalytical laboratory and CRO services for pharmaceutical and biotechnology sponsors developing drugsNew on EvolcKeybio
Microbiological testing and regulatory support for industrial product developers and manufacturersNew on EvolcKimialys
Biosensing surface chemistry and lateral flow assay development for diagnostics and drug discovery labsNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Content management
- SquarespaceHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.
